DRL-Header DRL-Header

X

Find Approved Drugs for Genetic Disease in Clinical Development in GERMANY

Loading...

All Data

Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

            Lead Product(s): Icatibant Acetate

            Therapeutic Area: Genetic Disease Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 01, 2020

            Details:

            Icatibant injection is therapeutically equivalent to Firazyr®, and supplied as a 3 mL prefilled, single-use syringe that is self-administered subcutaneously into the abdominal area.